» Articles » PMID: 16650524

Lactoferrin Potently Inhibits Osteoblast Apoptosis, Via an LRP1-independent Pathway

Overview
Date 2006 May 3
PMID 16650524
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Lactoferrin induces osteoblast proliferation in vitro and is anabolic to bone in vivo. We recently reported that the low-density lipoprotein-receptor-related protein 1 (LRP1), a multifunctional member of the LDL receptor family, transduces the mitogenic signal activated by lactoferrin. Here we investigate the effects of lactoferrin on osteoblast survival. At periphysiological concentrations (1-10mug/ml), lactoferrin protects both primary rat osteoblastic cells and SaOS2 cells from apoptosis induced by serum withdrawal. Surprisingly, this effect was not sensitive to the LRP1/2 inhibitor receptor-associated protein (RAP). Neither did lactoferrin selectively prevent apoptosis in fibroblastic cells expressing wild-type LRP1 compared to LRP1-null fibroblasts. Lactoferrin activates PI3 kinase-dependent Akt signaling in osteoblasts but this effect is neither LRP1-dependent nor required for lactoferrin-induced cell survival. Lactoferrin activates p42/44 MAPK signaling, but inhibiting this process does not abrogate its pro-survival actions. These results demonstrate that lactoferrin promotes osteoblast survival, an effect that may contribute to its anabolic skeletal actions in vivo. Our data also suggest that the molecular mechanisms that underpin the ability of lactoferrin to promote cell survival differ fundamentally from those which subserve its mitogenic actions, in particular being mediated by a distinct cell-membrane-based receptor.

Citing Articles

Antioxidant Potential of Lactoferrin and Its Protective Effect on Health: An Overview.

Rascon-Cruz Q, Siqueiros-Cendon T, Sianez-Estrada L, Villasenor-Rivera C, Angel-Lerma L, Olivas-Espino J Int J Mol Sci. 2025; 26(1.

PMID: 39795983 PMC: 11719613. DOI: 10.3390/ijms26010125.


The role of lactoferrin in bone remodeling: evaluation of its potential in targeted delivery and treatment of metabolic bone diseases and orthopedic conditions.

Tian M, Han Y, Yang G, Li J, Shi C, Tian D Front Endocrinol (Lausanne). 2023; 14:1218148.

PMID: 37680888 PMC: 10482240. DOI: 10.3389/fendo.2023.1218148.


Pharmacological and Non-Pharmacological Agents versus Bovine Colostrum Supplementation for the Management of Bone Health Using an Osteoporosis-Induced Rat Model.

Kydonaki E, Freitas L, Reguengo H, Simon C, Bastos A, Fernandes E Nutrients. 2022; 14(14).

PMID: 35889794 PMC: 9317446. DOI: 10.3390/nu14142837.


The Lactoferrin Phenomenon-A Miracle Molecule.

Kowalczyk P, Kaczynska K, Kleczkowska P, Bukowska-Osko I, Kramkowski K, Sulejczak D Molecules. 2022; 27(9).

PMID: 35566292 PMC: 9104648. DOI: 10.3390/molecules27092941.


Bovine Colostrum Supplementation Improves Bone Metabolism in an Osteoporosis-Induced Animal Model.

Kydonaki E, Freitas L, Fonseca B, Reguengo H, Simon C, Bastos A Nutrients. 2021; 13(9).

PMID: 34578859 PMC: 8471956. DOI: 10.3390/nu13092981.